Interferon-λ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease

Nature Communications

Volumn 6, Issue , 2015, Pages

  Eslam, Mohammed ^a   Hashem, Ahmed M ^b   Leung, Reynold ^a   Romero Gomez, Manuel ^c   Berg, Thomas ^d,e   Dore, Gregory J ^f,g   Chan, Henry L K ^h   Irving, William L ⁱ   Sheridan, David ^j,k   Abate, Maria L ^l   Adams, Leon A ^m   Mangia, Alessandra ⁿ   Weltman, Martin ^o   Bugianesi, Elisabetta ^l   Spengler, Ulrich ^p   Shaker, Olfat ^q   Fischer, Janett ^d   Mollison, Lindsay ^r   Cheng, Wendy ^s   Powell, Elizabeth ^t,u   Nattermann, Jacob ^p   Riordan, Stephen ^v   McLeod, Duncan ^w   Armstrong, Nicola J ^a   Douglas, Mark W ^a   Liddle, Christopher ^a   Booth, David R ^a   George, Jacob ^a   Ahlenstiel, Golo ^a   Ampuero, Javier ^c   Bassendine, Margaret ^j   Wong, Vincent W S ^h   Rosso, Chiara ^l   White, Rose ^a   Mezzabotta, Lavinia ^l   Suppiah, Vijayaprakash ^a   Michalk, Monika ^p   Malik, Barbara ^d   Matthews, Gail ^f   Applegate, Tanya ^f   Grebely, Jason ^f   Fragomeli, Vincenzo ^o   Jonsson, Julie R ^t   Santaro, Rosanna ⁿ   more..

^a UNIVERSITY OF SYDNEY   (Australia)

^b Minia University   (Egypt)

^c HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^f UNIVERSITY OF NEW SOUTH WALES   (Australia)

^g ST VINCENT S HOSPITAL   (Australia)

^h CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

ⁱ UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^j NEWCASTLE UNIVERSITY   (United Kingdom)

^k UNIVERSITY OF PLYMOUTH   (United Kingdom)

^l UNIVERSITY OF TURIN   (Italy)

^m UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

ⁿ CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^o NEPEAN HOSPITAL   (Australia)

^p UNIVERSITY OF BONN   (Germany)

^q CAIRO UNIVERSITY   (Egypt)

^r FREMANTLE HOSPITAL   (Australia)

^s ROYAL PERTH HOSPITAL   (Australia)

^t PRINCESS ALEXANDRA HOSPITAL   (Australia)

^u UNIVERSITY OF QUEENSLAND   (Australia)

^v UNIVERSITY OF NEW SOUTH WALES   (Australia)

^w WESTMEAD HOSPITAL   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; IFNL4 PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE;

ETIOLOGY; FATTY ACID; GASTROENTERITIS; GENOTYPE; HEPATITIS; MORTALITY; NUCLEIC ACID; POLYMORPHISM; PROTEIN;

ADULT; AGED; ARTICLE; CHRONIC LIVER DISEASE; COHORT ANALYSIS; DISEASE COURSE; DISEASE SEVERITY; FEMALE; GENOTYPE; HEPATITIS B; HEPATITIS C; HUMAN; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NONALCOHOLIC FATTY LIVER; PREDICTOR VARIABLE; RISK FACTOR; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; CHRONIC HEPATITIS; CLINICAL TRIAL; COMPLICATION; GENETICS; LIVER; LIVER CIRRHOSIS; MULTICENTER STUDY; NONPARAMETRIC TEST; PATHOLOGY; STATISTICAL MODEL;

HEPATITIS C VIRUS;

COHORT STUDIES; FEMALE; GENOTYPE; HEPATITIS, CHRONIC; HUMANS; INTERLEUKINS; LIVER; LIVER CIRRHOSIS; LOGISTIC MODELS; NON-ALCOHOLIC FATTY LIVER DISEASE; POLYMORPHISM, SINGLE NUCLEOTIDE; SEX FACTORS; STATISTICS, NONPARAMETRIC;

EID: 84924362729     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms7422     Document Type: Article

References (52)

1. Wynn, A. Cellular and molecular mechanisms of fibrosis. J. Pathol. 214, 199-210 (2008).
2. Iredale, J. P. Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ. J. Clin. Invest. 117, 539-548 (2007).
3. Mehal, W. Z., Iredale, J. & Friedman, S. L. Scraping fibrosis: expressway to the core of fibrosis. Nat. Med. 17, 552-553 (2011).
4. Romero-Gomez, M., Eslam, M., Ruiz, A. & Maraver, M. Genes and hepatitis C: susceptibility, fibrosis progression and response to treatment. Liver Int. 31, 443-460 (2011).
5. Patel, K. et al. HLA class I allelic diversity and progression of fibrosis in patients with chronic hepatitis C. Hepatology 43, 241-249 (2006).
6. Knapp, S. et al. Polymorphisms in interferon-induced genes and the outcome of hepatitis C virus infection: roles of MxA, OAS-1 and PKR. Genes Immun. 4, 411-419 (2003).
7. Ge, D. et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461, 399-401 (2009).
8. Suppiah, V. et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat. Genet. 41, 1100-1104 (2009).
9. Tanaka, Y. et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat. Genet. 41, 1105-1109 (2009).
10. Eslam, M. et al. IFNL3 polymorphisms predict response to therapy in chronic hepatitis C genotype 2/3 infection. J. Hepatol. 61, 235-241 (2014).
11. Prokunina-Olsson, L. et al. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat. Genet. 45, 164-171 (2013).
12. Bochud, P. Y. et al. IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes. Hepatology 55, 384-394 (2012).
13. Noureddin, M. et al. Association of IL28B genotype with fibrosis progression and clinical outcomes in patients with chronic hepatitis C: A longitudinal analysis. Hepatology 58, 1548-1557 (2013).
14. Thompson, A. J. et al. Genome wide-association study identifies IL28B polymorphism to be associated with baseline ALT and hepatic necroinflammatory activity in chronic hepatitis C patients enrolled in the IDEAL study (Abstract). Hepatology 52, 1220A (2010).
15. Marabita, F. et al. Genetic variation in the interleukin-28B gene is not associated with fibrosis progression in patients with chronic hepatitis C and known date of infection. Hepatology 54, 1127-1134 (2011).
16. Di Marco, V. et al. IL28B polymorphisms influence stage of fibrosis and spontaneous or interferon-induced viral clearance in thalassemia patients with hepatitis C virus infection. Haematologica 97, 679-686 (2012).
17. Fabris, C. et al. IL-28B rs12979860 C/T allele distribution in patients with liver cirrhosis: role in the course of chronic viral hepatitis and the development of HCC. J. Hepatol. 54, 716-722 (2011).
18. Falleti, E. et al. Role of interleukin 28B rs12979860 C/T polymorphism on the histological outcome of chronic hepatitis C: relationship with gender and viral genotype. J. Clin. Immunol. 31, 891-899 (2011).
19. Abe, H. et al. Common variation of IL28 affects gamma-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patients. J. Hepatol. 53, 439-443 (2010).
20. Garrett, M. E. et al. IL28B rs12979860 is not associated with histologic features of NAFLD in a cohort of Caucasian North American patients. J. Hepatol. 58, 402-403 (2013).
21. Petta, S. et al. IL28B and PNPLA3 polymorphisms affect histological liver damage in patients with non-alcoholic fatty liver disease. J. Hepatol. 56, 1356-1362 (2012).
22. Poynard, T. et al. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J. Hepatol. 34, 730-739 (2001).
23. Ghany, M. G. et al. Progression of fibrosis in chronic hepatitis C. Gastroenterology 124, 97-104 (2003).
24. Ryder, S. D., Irving, W. L., Jones, D. A., Neal, K. R. & Underwood, J. C. Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study. Gut 53, 451-455 (2004).
25. Sato, M. et al. Impact of IL28B genetic variation on HCV-induced liver fibrosis, inflammation, and steatosis: a meta-analysis. PLoS One 9, e91822 (2014).
26. Villa, E. et al. Reproductive status is associated with the severity of fibrosis in women with hepatitis C. PLoS One 7, e44624 (2012).
27. Poynard, T., Bedossa, P. & Opolon, P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet. 349, 825-832 (1997).
28. Lawson, A. et al. Hepatitis C virus-infected patients with a persistently normal alanine aminotransferase: do they exist and is this really a group with mild disease? J. Viral Hepatol. 17, 51-58 (2010).
29. Baran, B. et al. Treatment failure may lead to accelerated fibrosis progression in patients with chronic hepatitis C. J. Viral Hepatol. 21, 111-120 (2014).
30. Probst, A. et al. Role of hepatitis C virus genotype 3 in liver fibrosis progression - a systematic review and meta-analysis. J. Viral Hepatol. 18, 745-759 (2011).
31. van der Meer, A. J. et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 308, 2584-2593 (2012).
32. Lagging, M. et al. Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms. PLoS One 6, e17232 (2011).
33. Grebely, J. et al. The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C Virus infection. Hepatology 59, 109-120 (2014).
34. Gomez-Santos, L. et al. Inhibition of natural killer cells protects the liver against acute injury in the absence of glycine N-methyltransferase. Hepatology 56, 747-759 (2012).
35. Suppiah, V. et al. IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European Cohort: a cross-sectional study. PLoS Med. 8, e1001092 (2011).
36. Kumar, V. et al. Genome-wide association study identifies a susceptibility locus for HCV induced hepatocellular carcinoma. Nat. Genet. 43, 455-458 (2011).
37. Zhang, H. et al. Genome-wide association study identifies 1p36.22 as a new susceptibility locus for hepatocellular carcinoma in chronic hepatitis B virus carriers. Nat. Genet. 42, 755-758 (2010).
38. McClellan, J. & King, M. C. Genetic heterogeneity in human disease. Cell 141, 210-217 (2010).
39. Lee, J. C. et al. Human SNP links differential outcomes in inflammatory and infectious disease to a FOXO3-regulated pathway. Cell 155, 57-69 (2013).
40. Bibert, S. et al. IL28B expression depends on a novel TT/-G polymorphism which improves HCV clearance prediction. J. Exp. Med. 210, 1109-1116 (2013).
41. McFarland, A. P. et al. The favorable IFNL3 genotype escapes mRNA decay mediated by AU-rich elements and hepatitis C virus-induced microRNAs. Nat. Immunol. 15, 72-79 (2014).
42. Smith, K. R. et al. Identification of improved IL28B SNPs and haplotypes for prediction of drug response in treatment of hepatitis C using massively parallel sequencing in a cross-sectional European cohort. Genome Med. 3, 57 (2011).
43. Sheahan, T. et al. Interferon lambda alleles predict innate antiviral immune responses and hepatitis C virus permissiveness. Cell Host Microbe 15, 190-202 (2014).
44. Raglow, Z., Thoma-Perry, C., Gilroy, R. & Wan, Y. J. IL28B genotype and the expression of ISGs in normal liver. Liver Int. 33, 991-998 (2013).
45. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 27, s5-10 (2004).
46. Colloredo, G., Guido, M., Sonzogni, A. & Leandro, G. Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. J. Hepatol. 39, 239-244 (2003).
47. Bedossa, P. & Poynard, T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 24, 289 (1996).
48. Kleiner, D. E. et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41, 1313-1321 (2005).
49. Solé, X., Guinó, E., Valls, J., Iniesta, R. & Moreno, V. SNPStats: a web tool for the analysis of association studies. Bioinformatics 22, 1928-1929 (2006).
50. Lewis, C. M. Genetic association studies: design, analysis and interpretation. Brief Bioinform. 3, 146-153 (2002).
51. Akaike, H. Fitting autoregressive models for prediction. Ann. Inst. Stat. Math. 21, 243-247 (1969).
52. Yi, Q., Wang, P. P. & Krahn, M. Improving the accuracy of long-term prognostic estimates in hepatitis C virus infection. J. Viral Hepatol. 11, 166-174 (2004).